PLRZNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Polyrizon Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026

$9.69−0.31 (-3.15%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 2.0
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Polyrizon has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Polyrizon filed with the SEC

Oct 5, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "POLYRIZON FILES FOR U.S. PATENT APPLICATION TO EXPAND IP MOAT AROUND INTRANASAL DRUG-DELIVERY PLATFORM"
EX-99.1 to Form 6-K
Sep 28, 2026, 4:15 PM ET
AS OF JUNE 30, 2026
EX-99.1 to Form 6-K
Sep 28, 2026, 4:15 PM ET
POLYRIZON LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2026
EX-99.2 to Form 6-K
Sep 4, 2026, 4:30 PM ET
PRESS RELEASE TITLED: "POLYRIZON LTD. ANNOUNCES CLOSING OF $4.0 MILLION REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT"
EX-99.1 to Form 6-K
Sep 4, 2026, 9:19 AM ET
PRESS RELEASE TITLED: "POLYRIZON LTD. ANNOUNCES $4.0 MILLION REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT"
EX-99.1 to Form 6-K
Aug 20, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "POLYRIZON COMPLETES CLINICAL SITE NETWORK FOR NASARIXTM STUDY AND ADVANCES TOWARD PATIENT ENROLLMENT"
EX-99.1 to Form 6-K
Jul 13, 2026, 4:00 PM ET
COMPENSATION POLICY FOR EXECUTIVE OFFICERS AND DIRECTORS
EX-99.1 to Form 6-K
Jul 2, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES SUCCESSFUL RESULTS FOR NASARIX BIOCOMPATIBILITY PROGRAM, SUPPORTING ADVANCEMENT TOWARDS FIRST IN HUMAN CLINICAL TRIAL"
EX-99.1 to Form 6-K
Jun 29, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "POLYRIZON MAKES STRONG PROGRESS: RECEIVES CENTRAL IRB APPROVAL FOR ITS ALLERGY BLOCKER CLINICAL TRIAL"
EX-99.1 to Form 6-K
Jun 17, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "POLYRIZON RECEIVES NOTICE OF U.S. PATENT PUBLICATION FOR MUCOADHESIVE DRUG DELIVERY PLATFORM"
EX-99.1 to Form 6-K
Jun 15, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "POLYRIZON ADVANCES NASARIX DEVELOPMENT WITH KEY HUMAN STUDY TO CHARACTERIZE NASAL RESIDENCE TIME AND SUPPORT FDA REGULATORY PATHWAY"
EX-99.1 to Form 6-K
Jun 10, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "POLYRIZON RECEIVES NOTICE OF EUROPEAN PATENT PUBLICATION FOR INNOVATIVE MUCOADHESIVE NASAL DRUG DELIVERY TECHNOLOGY"
EX-99.1 to Form 6-K
Jun 8, 2026, 4:00 PM ET
NOTICE AND PROXY STATEMENT FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JULY 13, 2026
EX-99.1 to Form 6-K
Jun 8, 2026, 4:00 PM ET
PROXY CARD FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JULY 13, 2026
EX-99.2 to Form 6-K
Jun 8, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "POLYRIZON MAKES STRONG CLINICAL PROGRESS: SECURES THREE U.S. SITES FOR NASARIX TRIAL"
EX-99.1 to Form 6-K
May 13, 2026, 9:27 AM ET
PRESS RELEASE TITLED: "POLYRIZON ADVANCES TOWARDS HUMAN CLINICAL TRIALS: SECURES FIRST U.S. CLINICAL SITE FOR NASARIXTM ALLERGY BLOCKER CLINICAL TRIAL"
EX-99.1 to Form 6-K
May 4, 2026, 8:53 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES U.S. PATENT EXPANSION FOR ITS INTRANASAL DRUG DELIVERY PLATFORM"
EX-99.1 to Form 6-K
Apr 27, 2026, 9:29 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES FILING OF EUROPEAN PATENT APPLICATION FOR ITS BREAKTHROUGH DRUG DELIVERY PLATFORM"
EX-99.1 to Form 6-K
Apr 8, 2026, 4:16 PM ET
PRESS RELEASE TITLED: "POLYRIZON LTD. ANNOUNCES $3.5 MILLION REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT"
EX-99.1 to Form 6-K
Mar 17, 2026, 8:30 AM ET
PRESS RELEASE TITLED: "POLYRIZON SIGNS AN AGREEMENT WITH LEADING GLOBAL PRECLINICAL CRO AS PART OF CLINICAL DEVELOPMENT PROGRAM"
EX-99.1 to Form 6-K
Mar 10, 2026, 8:24 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES GMP MANUFACTURING OF CLINICAL TRIAL MATERIAL (CTM) WITH EUROFINS CDMO AMATSIAQUITAINE S.A.S FOR PLANNED U.S. CLINICAL STUDY"
EX-99.1 to Form 6-K
Feb 26, 2026, 8:14 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES SUCCESSFUL STUDY OF ITS NALOXONE FORMULATION DEMONSTRATING ENHANCED NASAL DEPOSITION PROFILE VERSUS COMMERCIAL REFERENCE PRODUCT"
EX-99.1 to Form 6-K
Feb 6, 2026, 7:58 AM ET
PRESS RELEASE TITLED: "POLYRIZON SIGNS AN AGREEMENT TO DEVELOP INTRANASAL PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN FORMULATION"
EX-99.1 to Form 6-K
Feb 4, 2026, 7:13 AM ET
PRESS RELEASE TITLED: "POLYRIZON INTENDS TO ACQUIRE 51% STAKE IN GLOBAL PRIVATE AVIATION COMPANY"
EX-99.1 to Form 6-K
Jan 22, 2026, 9:28 AM ET
PRESS RELEASE TITLED: "POLYRIZON ADVANCES REGULATORY PATH WITH INITIATION OF USABILITY STUDY PROGRAM FOR NASARIX ALLERGY BLOCKER"
EX-99.1 to Form 6-K
Jan 8, 2026, 8:47 AM ET
PRESS RELEASE TITLED: "POLYRIZON COMPLETES BRANDING PROCESS FOR PL-14 ALLERGY BLOCKER WITH BRAND NAME NASARIX TM"
EX-99.1 to Form 6-K
Jan 5, 2026, 9:09 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES NEW PRE-CLINICAL RESULTS: PL-14 DEMONSTRATES SIGNIFICANT ALLERGEN-BLOCKING PERFORMANCE COMPARED TO A STANDARD COMPARATOR"
EX-99.1 to Form 6-K
Dec 29, 2025, 7:59 AM ET
PRESS RELEASE TITLED: "POLYRIZON TO EXPLORE REVENUE-GENERATING REAL ASSET OPPORTUNITIES, LEVERAGING STRONG CASH POSITION AND DEBT-FREE BALANCE SHEET"
EX-99.1 to Form 6-K
Dec 19, 2025, 8:23 AM ET
PRESS RELEASE TITLED: "POLYRIZON SUBMITS PRE-REQUEST FOR DESIGNATION TO FDA FOR PL-16 VIRAL BLOCKER DESIGNED TO REDUCE THE EXPOSURE TO INFLUENZA AND COLD VIRUSES"
EX-99.1 to Form 6-K
Dec 11, 2025, 8:21 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES PROMISING PERMEATION KINETICS SUPPORTING ADVANCEMENT OF ITS INTRANASAL NALOXONE HYDROGEL PROGRAM"
EX-99.1 to Form 6-K
Dec 8, 2025, 9:00 AM ET
PRESS RELEASE TITLED: "POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKER NASAL SPRAY"
EX-99.1 to Form 6-K
Dec 3, 2025, 4:01 PM ET
PRESS RELEASE TITLED: "POLYRIZON REPORTS POSITIVE MUCOADHESION RESULTS FOR INTRANASAL NALOXONE HYDROGEL COMPARED TO MARKETED INTRANASAL NALOXONE PRODUCT"
EX-99.1 to Form 6-K
Dec 2, 2025, 7:57 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES SUCCESSFUL COMPLETION OF KEY MANUFACTURING UPSCALING MILESTONE FOR ITS NASAL SPRAY PLATFORM"
EX-99.1 to Form 6-K
Nov 6, 2025, 10:04 AM ET
PRESS RELEASE TITLED: "POLYRIZON DEMONSTRATES REVERSIBLE BROAD-SPECTRUM VIRAL BLOCKING BY ITS INTRANASAL BARRIER-FORMING FORMULATION"
EX-99.1 to Form 6-K
Oct 6, 2025, 8:36 AM ET
PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES POSITIVE PRE-CLINICAL RESULTS: PL-14 DEMONSTRATES ENCOURAGING ALLERGEN-BLOCKING EFFICACY"
EX-99.1 to Form 6-K
Sep 19, 2025, 8:39 AM ET
PRESS RELEASE TITLED: "POLYRIZON SUBMITS PRE-SUB PACKAGE TO THE FDA FOR PL-14 ALLERGY BLOCKER"
EX-99.1 to Form 6-K
Sep 17, 2025, 4:15 PM ET
AS OF JUNE 30, 2025
EX-99.1 to Form 6-K
Sep 17, 2025, 4:15 PM ET
POLYRIZON LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2025
EX-99.2 to Form 6-K
Aug 14, 2025, 8:39 AM ET
PRESS RELEASE TITLED: "POLYRIZON REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS"
EX-99.1 to Form 6-K
Jul 31, 2025, 4:19 PM ET
NOTICE AND PROXY STATEMENT FOR THE SPECIAL GENERAL MEETING TO BE HELD ON SEPTEMBER 4, 2025
EX-99.1 to Form 6-K